New regimen for Helicobacter pylori infection

Proton pump inhibitor, bismuth, amoxicillin, and metronidazole as first-line therapy for Helicobacter pylori infection

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003499

Enrollment

Registered

2019-02-13

Start date

2018-06-12

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Subjects receive rabeprazole (20 mg), bismuth (600 mg), amoxicillin (1 mg) and metronidazole (500 mg) twice a day for 2 weeks, After 4 weeks, eradication is confirmed using urea breath test.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults older than 19 and younger than 80 are eligible. Patients with peptic ulcer disease, gastric neoplasms, gastric MALT lymphoma, chronic gastritis with Helicobacter pylori infection are included in the study.

Exclusion criteria

Exclusion criteria: Patients with previous Helicobacter pylori eradication therapy, patients with stomach or esophageal surgery, patients with pregnancy or lactation, patients with renal or hepatic dysfunction, patients with previous history of allergy or hypersensitivity reactions to drugs, patients with infectious mononucleosis, Patients with hematologic disorders, patients with nervous system disease are excluded.

Design outcomes

Primary

Measure	Time frame
erdiaction rate	—

Secondary

Measure	Time frame
adverse events;Eradication rate according to antibiotic resistance	—

Countries

Korea, Republic of

Contacts

Public ContactWonhee Jeoung

Asan Medical Center

wish-88@naver.com+82-2-3010-5739

Outcome results